Bio-Techne (TECH) Cash Flow: Operating & Free Cash Flow

Bio-Techne (TECH) Cash Flow Statement

In fiscal 2026 (fiscal year ended Jun 30, 2026), Bio-Techne generated $292.07M of operating cash flow and spent $28.85M on capital expenditures. That left free cash flow of $263.22M, up 2.6% from $256.55M a year earlier, or 21.7% of revenue. It returned $91.59M to shareholders through $49.92M in dividends and $41.67M in share buybacks.

Bio-Techne Cash Flow Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Cash flow statement showing operating, investing, and financing activities for Bio-Techne Corporation (TECH) - Annual data in millions USD
Breakdown	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Jun 2026	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020	Jun 2019	Jun 2018	Jun 2017
Operating Activities
Net Income	181.86	73.40	168.11	285.44	263.10	139.59	229.30	96.07	126.15	76.09
Depreciation & Amortization	97.36	109.90	111.71	107.24	101.07	87.75	82.74	78.17	64.46	60.04
Deferred Income Tax	13.20	-51.11	-39.45	-29.57	6.82	-27.43	13.13	-13.58	-46.72	-3.43
Stock Based Compensation	41.37	40.83	38.04	39.23	42.18	48.98	32.37	32.28	28.24	14.63
Change in Working Capital	-41.30	11.54	-10.11	-90.58	-69.52	29.26	-5.25	-27.75	1.90	-13.93
Change in Accounts Receivable	-10.79	42.60	-20.53	-20.87	-57.60	-15.55	6.56	-2.70	-308.66	-19.69
Change in Inventory	-8.23	-18.14	-14.22	-30.17	-32.01	-7.14	-14.86	-13.65	-13.33	-0.73
Change in Accounts Payable	3.18	-13.95	15.17	-7.91	12.74	19.09	10.34	6.10	5.03	5.70
Change in Other Working Capital	-25.46	1.04	-0.76	-4.59	-3.08	32.86	-7.28	-17.51	318.86	0.79
Other Operating Activities	-0.41	102.99	-0.76	-86.94	-11.56	74.02	-147.07	16.43	-3.67	10.06
Net Cash from Operating Activities	292.07	287.56	298.98	254.39	325.27	352.16	205.22	181.62	170.37	143.45
Investing Activities
Capital Expenditures	-28.85	-31.01	-62.88	-38.24	-44.91	-44.30	-51.74	-25.41	-20.93	-15.18
Acquisitions	4.62	-15.00	-169.71	-101.18	0.00	-225.91	1.91	-289.49	-46.28	-293.79
Purchases of Investments	0.00	0.00	-5.53	-20.50	-78.00	-39.68	-70.19	-43.48	-8.57	-3.07
Sales/Maturities of Investments	6.04	1.09	28.08	-123.55	26.06	66.38	147.12	21.58	36.39	6.08
Other Investing Activities	0.00	9.74	7.00	-232.00	-25.00	0.00	0.00	-21.90	0.68	-36.99
Net Cash from Investing Activities	-18.19	-35.18	-203.03	-265.65	-96.85	-243.52	27.10	-336.80	-38.71	-305.95
Financing Activities
Debt Repayment	-146.00	27.00	-256.00	-525.66	-175.00	-15.50	-148.50	166.50	-4.50	252.00
Common Stock Issued	80.62	0.00	60.94	29.81	77.16	0.00	0.00	0.00	19.17	5.26
Common Stock Repurchased	-41.68	-275.73	-80.04	-19.56	-160.95	-43.18	-50.11	-15.41	0.00	0.00
Dividends Paid	-49.92	-50.39	-50.42	-50.29	-50.19	-49.62	-48.90	-48.36	-47.97	-47.33
Other Financing Activities	-12.14	45.22	-21.87	-2.46	0.09	45.75	63.71	31.65	-46.72	-15.56
Net Cash from Financing Activities	-169.11	-253.91	-122.40	22.62	-242.85	-62.55	-183.80	134.38	-99.19	189.39
Summary
Effect of Forex Changes on Cash	-2.24	11.93	-2.33	-3.36	-12.09	6.37	-2.77	-0.31	-2.09	0.50
Net Change in Cash	102.53	10.40	-28.78	8.00	-26.52	52.47	45.74	-21.10	30.38	27.38
Cash at Beginning of Period	162.19	151.79	180.57	172.57	199.09	146.63	100.89	121.99	91.61	64.24
Cash at End of Period	264.71	162.19	151.79	180.57	172.57	199.09	146.63	100.89	121.99	91.61
Free Cash Flow	263.22	256.55	236.10	216.15	280.36	307.86	153.47	156.21	149.43	128.27
Supplemental Disclosures
Interest Paid	-	18.96	14.50	8.37	11.03	13.58	-	-	-	-
Income Taxes Paid	-	74.36	65.25	88.43	30.34	20.95	-	-	-	-

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Bio-Techne Cash Flow

What is Bio-Techne's free cash flow?

Bio-Techne generated free cash flow of $263.22M in fiscal 2026 (fiscal year ended Jun 30, 2026), operating cash flow of $292.07M minus $28.85M of capital expenditures. That was up 2.6% from $256.55M a year earlier. Free cash flow equaled 21.7% of revenue.

How much does Bio-Techne spend on capital expenditures?

Bio-Techne spent $28.85M on capital expenditures in fiscal 2026, compared with $31.01M a year earlier. That equals 9.9% of operating cash flow.

Does Bio-Techne pay dividends or buy back shares?

Yes. In fiscal 2026 Bio-Techne returned $49.92M in dividends and $41.67M in share buybacks to shareholders, according to its cash flow statement.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition